Svitlana Tatulych

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

Roy Fleischmann, Eduardo Mysler, Stephen Hall et al. · The Lancet · 2017 · 479 citations

Rheumatoid Disorder, Rheumatology, Tofacitinib Monotherapy +8

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Eric L. Simpson, Rodney Sinclair, Seth Forman et al. · The Lancet · 2020 · 452 citations · Full text

Allergy, Atopic Dermatitis, Medicine +9

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study

Kim Papp, James G. Krueger, Steven R. Feldman et al. · Journal of the American Academy of Dermatology · 2016 · 151 citations · Full text

Tofacitinib attenuates pathologic immune pathways in patients with psoriasis: A randomized phase 2 study

James G. Krueger, James D. Clark, Mayte Suárez‐Fariñas et al. · Journal of Allergy and Clinical Immunology · 2016 · 139 citations · Full text

Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis

Joseph F. Merola, Boni E. Elewski, Svitlana Tatulych et al. · Journal of the American Academy of Dermatology · 2017 · 95 citations · Full text